mRNA future
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024
Moderna, today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345),
an mRNA respiratory syncytial virus (RSV) vaccine,
to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna.
Stéphane Bancel, Chief Executive Officer of Moderna.
The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform
Moderna expects to have mRESVIA available for eligible populations in the U.S. by the 2024/2025 respiratory virus season.
Moderna has filed for mRNA-1345 approval with regulators in multiple markets around the world.
Moderna races ahead in flu and Covid-19 combo vaccine race with Phase III win
Moderna injection mRNA-1083
Comprises a seasonal influenza vaccine candidate, mRNA-1010,
and a next-generation Covid-19 vaccine prospect called mRNA-1283.
Moderna announces positive data from a Phase III trial of its mRNA vaccine candidate.
Now, in a Phase III trial (NCT06097273) for mRNA-1083
Moderna
“statistically significantly higher immune responses” compared to existing vaccines on the market.
The trial met its primary endpoints, Moderna said in a 10 June press release.
Immune response was seen across three influenza virus strains (H1N1, H3N2, and B/Victoria) and against SARS-CoV-2.
Although Moderna has not published the full dataset from the Phase III trial,
it plans to present the results in more detail at an upcoming medical conference,
in addition to a submission for publication.
The company said it “will engage with regulators on next steps”.
Other mRNA vaccines in development
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Cytomegalovirus (CMV)
CMVictory is a pivotal Phase 3 trial evaluating mRNA-1647 against primary CMV infection in women 16 to 40 years of age.
Epstein-Barr virus (EBV)
mRNA-1189
The randomized, observer-blind, placebo-controlled study is fully enrolled.
Herpes simplex virus (HSV)
mRNA-1608
Phase 1/2 trial
The randomized 1:1:1:1, observer-blind, controlled study is fully enrolled with 300 participants in the U.S.
Varicella-Zoster virus (VZV)
Moderna's VZV vaccine candidate mRNA-1468 has initial data available from a Phase 1/2 trial
Norovirus
The Company is advancing mRNA-1403 toward a pivotal Phase 3 trial.
-
2:08:53
vivafrei
20 hours agoEp. 252: Liberals DISQUALIFY Candidate from Race! DOGE Wins & Loses; Rumble Sues BRAZIL! & MORE!
148K250 -
1:15:12
Josh Pate's College Football Show
11 hours ago $21.27 earnedCFB’s Top 12 Programs | TV Executives & Our Sport | USC Changes Coming | Early Championship Picks
88.1K2 -
LIVE
Vigilant News Network
15 hours agoUK Government BUSTED in Secret Plot to Extract Your Data | Media Blackout
1,734 watching -
1:03:32
Winston Marshall
3 days ago"War On Children!" The DEMISE Of The West Starts With Schools - Katharine Birbalsingh
119K67 -
48:02
Survive History
18 hours ago $8.11 earnedCould You Survive as a Sharpshooter in the Napoleonic Wars?
68.7K3 -
12:03
Space Ice
18 hours agoSteven Seagal's China Salesman - Mike Tyson Knocks Him Out - Worst Movie Ever
50.8K19 -
11:37
Degenerate Jay
18 hours ago $19.35 earnedJames Bond Needs Quality Over Quantity From Amazon
120K10 -
15:23
Misha Petrov
18 hours agoTrad Wives & Girl Bosses Go to WAR!
87.2K52 -
2:03:11
TheDozenPodcast
16 hours agoFootball villain fighting the state: Joey Barton
62.8K1 -
13:18:50
Scottish Viking Gaming
19 hours ago💚Rumble :|: Sunday Funday :|: Smash the Blerps and Vape the Terpes
98.9K8
6 Comments